| pubmed-article:7585540 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7585540 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:7585540 | lifeskim:mentions | umls-concept:C0025202 | lld:lifeskim |
| pubmed-article:7585540 | lifeskim:mentions | umls-concept:C0254610 | lld:lifeskim |
| pubmed-article:7585540 | lifeskim:mentions | umls-concept:C0024264 | lld:lifeskim |
| pubmed-article:7585540 | lifeskim:mentions | umls-concept:C0007613 | lld:lifeskim |
| pubmed-article:7585540 | lifeskim:mentions | umls-concept:C0022687 | lld:lifeskim |
| pubmed-article:7585540 | lifeskim:mentions | umls-concept:C1510986 | lld:lifeskim |
| pubmed-article:7585540 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:7585540 | lifeskim:mentions | umls-concept:C0441712 | lld:lifeskim |
| pubmed-article:7585540 | pubmed:issue | 21 | lld:pubmed |
| pubmed-article:7585540 | pubmed:dateCreated | 1995-12-6 | lld:pubmed |
| pubmed-article:7585540 | pubmed:abstractText | Interleukin 15 (IL-15) is a novel cytokine that shares no homology with IL-2, but it requires the use of beta and gamma chains of the IL-2 receptor complex for binding and signaling. In vitro studies have shown induction of CTL and lymphokine-activated killer (LAK) cell activity in peripheral blood mononuclear cells (PBMCs) from normal donors by IL-15 against known tumor targets. The present study attempts to define the role of IL-15 in generating LAK activity from melanoma patient lymphocytes. PBMCs of patients newly diagnosed with metastatic melanoma were incubated with different doses of recombinant human IL-15 and tested against autologous tumor cells, LAK sensitive cell lines (i.e., FMEX and Daudi), as well as the natural killer-sensitive cell line K562, in a 15-h 51Cr release assay. The effect of IL-15 was found to be both time and dose dependent, with peak activity detected after 2 or 3 days of culture with 100 ng/ml of this cytokine. LAK and not CTL activity in patient PBMCs was detected by the inability of mAbs against CD4, CD8, and MHC class I to effectively block lysis of autologous tumor and FMEX melanoma cells. In addition, interaction via the CD18 adhesion molecule was shown to be critical in IL-15-induced LAK-mediated lysis of autologous tumor cells. Finally, incubation of patient PBMCs with IL-15 for 6 h resulted in the up-regulation of perforin mRNA transcription. These findings suggest that LAK activity can be generated from melanoma patient PBMCs in the presence of IL-15 to lyse autologous tumor cells in a non-MHC-restricted manner. This new cytokine may play an important role in antitumor immunity with a possible use for cancer immunotherapy. | lld:pubmed |
| pubmed-article:7585540 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7585540 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7585540 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7585540 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7585540 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7585540 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7585540 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7585540 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7585540 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7585540 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:7585540 | pubmed:issn | 0008-5472 | lld:pubmed |
| pubmed-article:7585540 | pubmed:author | pubmed-author:DjeuJ YJY | lld:pubmed |
| pubmed-article:7585540 | pubmed:author | pubmed-author:ReintgenD SDS | lld:pubmed |
| pubmed-article:7585540 | pubmed:author | pubmed-author:PuleoC ACA | lld:pubmed |
| pubmed-article:7585540 | pubmed:author | pubmed-author:UsseryDD | lld:pubmed |
| pubmed-article:7585540 | pubmed:author | pubmed-author:GameroA MAM | lld:pubmed |
| pubmed-article:7585540 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7585540 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:7585540 | pubmed:volume | 55 | lld:pubmed |
| pubmed-article:7585540 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7585540 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7585540 | pubmed:pagination | 4988-94 | lld:pubmed |
| pubmed-article:7585540 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:7585540 | pubmed:meshHeading | pubmed-meshheading:7585540-... | lld:pubmed |
| pubmed-article:7585540 | pubmed:meshHeading | pubmed-meshheading:7585540-... | lld:pubmed |
| pubmed-article:7585540 | pubmed:meshHeading | pubmed-meshheading:7585540-... | lld:pubmed |
| pubmed-article:7585540 | pubmed:meshHeading | pubmed-meshheading:7585540-... | lld:pubmed |
| pubmed-article:7585540 | pubmed:meshHeading | pubmed-meshheading:7585540-... | lld:pubmed |
| pubmed-article:7585540 | pubmed:meshHeading | pubmed-meshheading:7585540-... | lld:pubmed |
| pubmed-article:7585540 | pubmed:meshHeading | pubmed-meshheading:7585540-... | lld:pubmed |
| pubmed-article:7585540 | pubmed:meshHeading | pubmed-meshheading:7585540-... | lld:pubmed |
| pubmed-article:7585540 | pubmed:meshHeading | pubmed-meshheading:7585540-... | lld:pubmed |
| pubmed-article:7585540 | pubmed:meshHeading | pubmed-meshheading:7585540-... | lld:pubmed |
| pubmed-article:7585540 | pubmed:meshHeading | pubmed-meshheading:7585540-... | lld:pubmed |
| pubmed-article:7585540 | pubmed:meshHeading | pubmed-meshheading:7585540-... | lld:pubmed |
| pubmed-article:7585540 | pubmed:meshHeading | pubmed-meshheading:7585540-... | lld:pubmed |
| pubmed-article:7585540 | pubmed:meshHeading | pubmed-meshheading:7585540-... | lld:pubmed |
| pubmed-article:7585540 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7585540 | pubmed:articleTitle | Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism. | lld:pubmed |
| pubmed-article:7585540 | pubmed:affiliation | Department of Biochemistry, University of South Florida, College of Medicine, Tampa, USA. | lld:pubmed |
| pubmed-article:7585540 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7585540 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:7585540 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7585540 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7585540 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7585540 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7585540 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7585540 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7585540 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7585540 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7585540 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7585540 | lld:pubmed |
